Unilife Corp

Unilife — Q1 FY2014 Earnings Presentation

9 slides from Unilife's earnings presentation, Nov 12, 2013

  1. Slide 1: Fiscal Year 2014 First Quarter Earnings Call

    Exhibit 99.2 st Fiscal Year 2014 Quarter 1 Earnings Call November 11, 2013 1

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    CautionaryNoteRegarding Forward-Looking Statements Thispresentationcontainsforward lookingstatementsunder the safeharbor provisionsof the USsecuritieslaws.Theseforward-lookingstatementsarebased on management’sbeliefsand assumptionsand on informationcurrently availableto our management. Ourmanagement

  3. Slide 3: Introductory Comments by Unilife CEO Alan Shortall

    Introductory Comments by Unilife CEO Alan Shortall Entered period of long-term partnerships and rapid revenue growth Received $5MM Sanofi payment (deferred revenue in Sep 30, 2013 balance sheet) Beginning to receive payments from other customers for active programs Sequential quarterly growth antici

  4. Slide 4: The Market for Wearable Injectors

    The Market for Wearable Injectors Estimated 350 million wearable injectors to be sold annually by 2024 $20 -$35 ASP /unit likely to translate into a market size of $8.8 billion by 2024 Projected CAGR of 138% from 2015 2020 - and 48% from 2020 – 2024 More than 110 high viscous and large volume market

  5. Slide 5: ReadyToGo Platform of Wearable Injectors

    ReadyToGo™ Platform of Wearable Injectors Pre-Filled. Pre-Assembled. Ready-to-Inject. Precision-Therapy™ Flex-Therapy™ For long-duration therapies that requireFor long-duration therapies that require delivery of delivery of large dose volumes large dose volumes with a specific rate profile 5

  6. Slide 6: Supply Contract with MedImmune

    Supply Contract with MedImmune MedImmune is the global biologics R&D arm of AstraZeneca One of the richest biologic portfolios in the industry 120 large molecule drugs in R&D (half of AstraZeneca’s total clinical pipeline) Under this agreement, Unilife will customize and supply devicesfrom its platf

  7. Slide 7: Financial Data

    Financial Data 1Q FY2014 1Q FY2013 Revenues $3.2MM $0.7MM Research & development $6.4MM $4.7MM Selling, general & administrative $6.5MM $6.6MM Net loss $11.2MM $12.5MM Net loss per share d–iluted $0.12 $0.16 Adjusted net loss $7.1MM $9.1MM Adjusted net loss per sharediluted - $0.08 $0.12 7

  8. Slide 8: Moving Forward

    Moving Forward Focused on rapid and significant growth in the long-term Anticipating sequential quarterly growth in FY2014 Annual growth year over prior year in FY2014 and beyond Continuing to increase investment in R&D and operations Much of our operating expenditure to be offset by increasing reve

  9. Slide 9: Questions

    Fiscal Year 2014 1 Quarter st Earnings Call Questions 9

Unilife — Q1 FY2014 Earnings Presentation on 6ix